3 results match your criteria: "Yale Affiliated Hospitals Program[Affiliation]"
Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.
Cureus
October 2024
Department of Medicine, Yale Affiliated Hospitals Program, New Haven, USA.
Article Synopsis
- * A literature search identified 95 relevant studies, revealing difficulties in diagnosing lean MASLD using traditional methods and highlighting the role of advanced imaging techniques.
- * The study recommends increased clinical awareness, regular monitoring, and tailored management strategies, such as lifestyle changes and potential medications, while calling for more research to improve diagnosis and treatment options.
Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease: A systematic review.
J Gastroenterol Hepatol
September 2024
Yale Affiliated Hospitals Program, Bridgeport, Connecticut, USA.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the global population, with a significant risk of advancing to liver cirrhosis and hepatocellular carcinoma. The roles of ammonia and glutamine in MASLD's pathogenesis are increasingly recognized, prompting this systematic review. This systematic review was conducted through a meticulous search of literature on December 21, 2023, across five major databases, focusing on studies that addressed the relationship between ammonia or glutamine and MASLD.
View Article and Find Full Text PDFFactors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.
Ann Hematol
February 2024
Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA.